Showcase session

Challenges and Developments in Nanogenotoxicology

Houston: 27th October

Professor Shareen Doak

Professor Shareen Doak is co-lead of the In Vitro Toxicology Research Group and leads prostate cancer research within the Cancer Biomarkers Group in Swansea University’s College of Medicine.

Her main research interests are focused on investigating the genotoxic profiles of engineered nanomaterials, their mechanism of action and subsequent consequences upon human health, developing alternative in vitro models for genotoxicity and carcinogenicity testing, and identifying and validating molecular biomarkers that predict the progression of prostate cancer to advanced invasive disease.

A UK and EUROTOX Registered Toxicologist, Shareen sits on the UK Committee on Mutagenicity (COM), International Genetic Toxicology Technical Committee (GTTC) and the EU Scientific Committee on Consumer Safety Working Group on Nanomaterials in Cosmetics (external expert). 

Research Groups

In Vitro Toxicology Group This group focuses on the mechanistic basis for DNA damage induction and persistence, as well as its consequences to human health. The approaches taken by this group involve models of human mutagenesis in vitro in human cells, including genetically modified repair deficient cells, to understand basic mechanisms. Recent work has also focused on assessing 3D human skin models for measuring DNA damage, coupled to automated micronucleus capabilities. 

Nano(geno)toxicology Research interests lie in understanding the mechanistic basis for DNA damage (genotoxicity) induction and persistence, as well as its consequences to human health following exposure to engineered nanomaterials. Research focuses on determining genotoxic potential as a function of nanomaterial physico-chemical characteristics and on developing in vitro test systems suited to the assessment of these novel substances.

Cancer Biomarkers Group Research within the prostate cancer sub-section of the Cancer Biomarkers Group focuses on the identification and validation of molecular biomarkers for the prediction of prostate cancer outcome. The ultimate aim is to achieve patient stratification according to risk for developing metastatic disease with such biomarkers, in order to improve the clinical management of patients.